Scientific work

Uzm. Dr. Uğur Özkerim

30 publications. The source of the information is stated next to each publication.

Back to profile

  1. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  2. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  3. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  4. Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62010099 PMID 41597386 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  5. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Open-access full textSource: OpenAlex

  6. Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study

    Oncology Letters, 2026

    DOI 10.3892/ol.2026.15750 PMID 42491228 Open-access full textSource: ORCID

  7. 486P Machine learning–based prediction of nivolumab response using systemic inflammatory biomarkers in advanced NSCLC: A real-world study

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.106800 Open-access full textSource: OpenAlex

  8. 105P HER2 amplification drives resistance to anti-EGFR therapy in RAS/BRAF wild-type metastatic colorectal cancer: A real-world study

    Annals of Oncology, 2026

    DOI 10.1016/j.annonc.2026.05.106 Open-access full textSource: OpenAlex

  9. Prognostic Impact of Immune-Related Adverse Events in Patients with Non–Small Cell Lung Cancer Treated with Second-Line Nivolumab: A Single-Center Real-World Experience

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.263046 Source: OpenAlex

  10. Pneumococcal Vaccination in Oncology Practice in Türkiye: Results of Patient and Physician Survey Studies

    Cerrahpaşa Medical Journal, 2026

    DOI 10.5152/cjm.2026.26011 Open-access full textSource: ORCID

  11. Impact of Post-chemotherapy Radiotherapy on Survival Outcomes in Inoperable Malignant Mesothelioma: A Single-center Retrospective Analysis

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-11 Open-access full textSource: ORCID

  12. The Comparison of Myocardial Dysfunction Using Speckle Tracking Echocardiography in Resistive and Non-Resistive Familial Mediterranean Fever Patients

    Southern Clinics of Istanbul Eurasia, 2026

    DOI 10.14744/scie.2026.32533 Open-access full textSource: OpenAlex

  13. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  14. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  15. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

    Journal of Personalized Medicine, 2025

    DOI 10.3390/jpm16010008 PMID 41590501 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  16. Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

    Medicina, 2025

    DOI 10.3390/medicina61050819 PMID 40428777 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  17. Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

    Medicina, 2025

    DOI 10.3390/medicina61071161 PMID 40731791 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  18. Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

    Pharmaceuticals, 2025

    DOI 10.3390/ph18060931 PMID 40573326 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  19. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

    Current Oncology, 2025

    DOI 10.3390/curroncol32090503 PMID 41002573 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  20. Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-1-1 Open-access full textSource: OpenAlex

  21. Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment

    Cancers, 2025

    DOI 10.3390/cancers17071076 PMID 40227569 Open-access full textSource: OpenAlex

  22. Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

    Healthcare, 2025

    DOI 10.3390/healthcare13151810 PMID 40805843 Open-access full textSource: OpenAlex

  23. Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25030 Open-access full textSource: OpenAlex

  24. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 citations (Europe PMC) Open-access full textSource: OpenAlex

  25. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

    Chemotherapy, 2024

    DOI 10.1159/000537874 PMID 38368871 5 citations (Europe PMC) Source: OpenAlex

  26. Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

    Medicina, 2024

    DOI 10.3390/medicina60122069 PMID 39768949 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  27. Which Labarotory Index is Better for Predicting Survival and Pathological Response in Patients with Breast Cancer Receiving NACT?

    Research Square, 2024

    DOI 10.21203/rs.3.rs-3854249/v1 Open-access full textSource: ORCID

  28. Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?

    Medicina Lithuania, 2023

    DOI 10.3390/medicina59030557 PMID 36984558 12 citations (Europe PMC) Open-access full textSource: ORCID

  29. The association of hemoglobin/red blood distribution width with overall survival: a retrospective analysis of melanoma

    Esperienze Dermatologiche, 2023

    DOI 10.23736/s1128-9155.23.00556-3 1 citation (OpenAlex) Source: OpenAlex

  30. AB1029 MYOCARDIAL DYSFUNCTION DETECTED BY USING SPECKLE TRACKING ECHOCARDIOGRAPHY IN FAMILIAL MEDITERRANEAN FEVER PATIENTS; IS THERE ANY DIFFERENCE REGARDING RESISTANT DISEASE?

    Annals of the Rheumatic Diseases, 2020

    DOI 10.1136/annrheumdis-2020-eular.4057 Open-access full textSource: OpenAlex